[{"innerBlocks":[],"name":"core\/freeform","postId":254,"blockType":{"name":"core\/freeform","keywords":[],"attributes":{"content":{"type":"string","source":"raw"},"lock":{"type":"object"}},"providesContext":[],"usesContext":[],"selectors":[],"supports":{"className":false,"customClassName":false,"reusable":false},"styles":[],"variations":[],"apiVersion":3,"title":"Classic","description":"Use the classic WordPress editor.","category":"text"},"originalContent":"A new data portal is providing medical researchers with de-identified information from 4,298 Parkinson\u2019s disease patients, including cerebrospinal fluid, DNA samples, plasma and RNA. \u201cThe portal enables researchers to study complex data sets and perform genome-wide analyses at a scale previously impossible,\u201d according to the National Institutes of Health.

The portal was launched by the Accelerating Medicines Partnership (AMP) program for Parkinson\u2019s disease (PD), a public-private partnership between NIH, the Food and Drug Administration, as well as industry partners Celgene, GSK, Pfizer, Sanofi, Verily and the non-profit Michael J. Fox Foundation for Parkinson\u2019s Research.\u201cOne important part of this platform is that, in addition to providing a place for storing complex data, we are also providing the tools to analyze that data within the platform itself,\u201d said Debra Babcock, MD, program director at National Institute of Neurological Disorders and Stroke and co-chair of the AMP PD Steering Committee. \u201cIn this way, we are bringing scientists to the data, which will increase opportunities for collaboration.\u201dAccording to NIH, one of the unique features of the data in the AMP PD Knowledge Portal is that they are longitudinal, allowing researchers to analyze data from across an individual\u2019s lifespan or disease course. The purpose is to provide a \u201cdeep molecular characterization and longitudinal clinical profiling of PD patient data and biosamples with the goal of identifying and validating diagnostic, prognostic and\/or disease progression biomarkers for Parkinson\u2019s disease.\u201d In addition, the AMP PD Knowledge Portal is able to incorporate other data sources and types such as proteomics\u2014a project that is currently planned.\u201cThe AMP model has provided a unique platform for bringing together diverse patient cohorts, advances in technology and scientific expertise to study Parkinson\u2019s disease on a scale that has not been attempted before,\u201d said David Wholley, senior vice president of research partnerships at the Foundation of the National Institutes of Health. \u201cWith the AMP PD Knowledge Portal, we are helping the scientific community worldwide to fast-track discoveries that we hope will ultimately help Parkinson\u2019s disease patients and their families.\u201d","saveContent":"A new data portal is providing medical researchers with de-identified information from 4,298 Parkinson\u2019s disease patients, including cerebrospinal fluid, DNA samples, plasma and RNA. \u201cThe portal enables researchers to study complex data sets and perform genome-wide analyses at a scale previously impossible,\u201d according to the National Institutes of Health.

The portal was launched by the Accelerating Medicines Partnership (AMP) program for Parkinson\u2019s disease (PD), a public-private partnership between NIH, the Food and Drug Administration, as well as industry partners Celgene, GSK, Pfizer, Sanofi, Verily and the non-profit Michael J. Fox Foundation for Parkinson\u2019s Research.\u201cOne important part of this platform is that, in addition to providing a place for storing complex data, we are also providing the tools to analyze that data within the platform itself,\u201d said Debra Babcock, MD, program director at National Institute of Neurological Disorders and Stroke and co-chair of the AMP PD Steering Committee. \u201cIn this way, we are bringing scientists to the data, which will increase opportunities for collaboration.\u201dAccording to NIH, one of the unique features of the data in the AMP PD Knowledge Portal is that they are longitudinal, allowing researchers to analyze data from across an individual\u2019s lifespan or disease course. The purpose is to provide a \u201cdeep molecular characterization and longitudinal clinical profiling of PD patient data and biosamples with the goal of identifying and validating diagnostic, prognostic and\/or disease progression biomarkers for Parkinson\u2019s disease.\u201d In addition, the AMP PD Knowledge Portal is able to incorporate other data sources and types such as proteomics\u2014a project that is currently planned.\u201cThe AMP model has provided a unique platform for bringing together diverse patient cohorts, advances in technology and scientific expertise to study Parkinson\u2019s disease on a scale that has not been attempted before,\u201d said David Wholley, senior vice president of research partnerships at the Foundation of the National Institutes of Health. \u201cWith the AMP PD Knowledge Portal, we are helping the scientific community worldwide to fast-track discoveries that we hope will ultimately help Parkinson\u2019s disease patients and their families.\u201d","order":0,"get_parent":{},"attributes":[],"attributesType":{"content":{"type":"string","source":"raw"},"lock":{"type":"object"}},"dynamicContent":""}]

Data portal offers de-identified info on patients with Parkinson’s

More for you